341 related articles for article (PubMed ID: 22500835)
41. A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF.
Hoatlin ME; Zhi Y; Ball H; Silvey K; Melnick A; Stone S; Arai S; Hawe N; Owen G; Zelent A; Licht JD
Blood; 1999 Dec; 94(11):3737-47. PubMed ID: 10572087
[TBL] [Abstract][Full Text] [Related]
42. The multi-faceted functioning portrait of LRF/ZBTB7A.
Constantinou C; Spella M; Chondrou V; Patrinos GP; Papachatzopoulou A; Sgourou A
Hum Genomics; 2019 Dec; 13(1):66. PubMed ID: 31823818
[TBL] [Abstract][Full Text] [Related]
43. Overexpression, purification, characterization, and crystallization of the BTB/POZ domain from the PLZF oncoprotein.
Li X; Lopez-Guisa JM; Ninan N; Weiner EJ; Rauscher FJ; Marmorstein R
J Biol Chem; 1997 Oct; 272(43):27324-9. PubMed ID: 9341182
[TBL] [Abstract][Full Text] [Related]
44. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation.
Chen W; Iida S; Louie DC; Dalla-Favera R; Chaganti RS
Blood; 1998 Jan; 91(2):603-7. PubMed ID: 9427715
[TBL] [Abstract][Full Text] [Related]
45. Control of lymphocyte differentiation by the LEF-1/TCF family of transcription factors.
Reya T; Okamura R; Grosschedl R
Cold Spring Harb Symp Quant Biol; 1999; 64():133-40. PubMed ID: 11232278
[No Abstract] [Full Text] [Related]
46. PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
Lu X; Fernando TM; Lossos C; Yusufova N; Liu F; Fontán L; Durant M; Geng H; Melnick J; Luo Y; Vega F; Moy V; Inghirami G; Nimer S; Melnick AM; Lossos IS
Blood; 2018 Nov; 132(19):2026-2039. PubMed ID: 30082494
[TBL] [Abstract][Full Text] [Related]
47. Stage-specific modulation of IFN-regulatory factor 4 function by Krüppel-type zinc finger proteins.
Gupta S; Anthony A; Pernis AB
J Immunol; 2001 May; 166(10):6104-11. PubMed ID: 11342629
[TBL] [Abstract][Full Text] [Related]
48. Internal deletions within the BCL6 gene in B-cell non-Hodgkin's lymphoma.
Nakamura Y
Leuk Lymphoma; 2000 Aug; 38(5-6):505-12. PubMed ID: 10953971
[TBL] [Abstract][Full Text] [Related]
49. Requirement for cyclin D3 in germinal center formation and function.
Peled JU; Yu JJ; Venkatesh J; Bi E; Ding BB; Krupski-Downs M; Shaknovich R; Sicinski P; Diamond B; Scharff MD; Ye BH
Cell Res; 2010 Jun; 20(6):631-46. PubMed ID: 20404856
[TBL] [Abstract][Full Text] [Related]
50. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.
Torlakovic E; Malecka A; Myklebust JH; Tierens A; Aasheim HC; Nesland JM; Smeland E; Kvaløy S; Delabie J
J Pathol; 2005 Jul; 206(3):312-9. PubMed ID: 15892171
[TBL] [Abstract][Full Text] [Related]
51. Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes.
Rivas MA; Durmaz C; Kloetgen A; Chin CR; Chen Z; Bhinder B; Koren A; Viny AD; Scharer CD; Boss JM; Elemento O; Mason CE; Melnick AM
Front Immunol; 2021; 12():688493. PubMed ID: 34621263
[TBL] [Abstract][Full Text] [Related]
52. Novel human BTB/POZ domain-containing zinc finger protein ZNF295 is directly associated with ZFP161.
Wang J; Kudoh J; Takayanagi A; Shimizu N
Biochem Biophys Res Commun; 2005 Feb; 327(2):615-27. PubMed ID: 15629158
[TBL] [Abstract][Full Text] [Related]
53. Acetylation inactivates the transcriptional repressor BCL6.
Bereshchenko OR; Gu W; Dalla-Favera R
Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
[TBL] [Abstract][Full Text] [Related]
54. Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.
Rivas MA; Meydan C; Chin CR; Challman MF; Kim D; Bhinder B; Kloetgen A; Viny AD; Teater MR; McNally DR; Doane AS; Béguelin W; Fernández MTC; Shen H; Wang X; Levine RL; Chen Z; Tsirigos A; Elemento O; Mason CE; Melnick AM
Nat Immunol; 2021 Feb; 22(2):240-253. PubMed ID: 33432228
[TBL] [Abstract][Full Text] [Related]
55. An expanding job description for bcl6.
Bi E; Ye BH
J Mol Cell Biol; 2010 Feb; 2(1):5-7. PubMed ID: 19797315
[TBL] [Abstract][Full Text] [Related]
56. BCL6 promoter interacts with far upstream sequences with greatly enhanced activating histone modifications in germinal center B cells.
Ramachandrareddy H; Bouska A; Shen Y; Ji M; Rizzino A; Chan WC; McKeithan TW
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11930-5. PubMed ID: 20547840
[TBL] [Abstract][Full Text] [Related]
57. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies.
Tsuboi K; Iida S; Inagaki H; Kato M; Hayami Y; Hanamura I; Miura K; Harada S; Kikuchi M; Komatsu H; Banno S; Wakita A; Nakamura S; Eimoto T; Ueda R
Leukemia; 2000 Mar; 14(3):449-56. PubMed ID: 10720141
[TBL] [Abstract][Full Text] [Related]
58. Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers.
Aggarwal A; Hunter WJ; Aggarwal H; Silva ED; Davey MS; Murphy RF; Agrawal DK
Exp Mol Pathol; 2010 Oct; 89(2):140-8. PubMed ID: 20471975
[TBL] [Abstract][Full Text] [Related]
59. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
60. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
